Abstracts

UNEQUAL DISTRIBUTION OF INTACT HIV PROVIRUSES IN CELLS EXPRESSING PD-1 AND/OR CTLA-4

Background: HIV persists in CD4 T-cells of people with HIV (PWH) on antiretroviral therapy (ART). Determining cell surface markers that enrich for genetically-intact HIV genomes is vital in developing curative strategies. The immune checkpoint markers programmed cell death protein-1 (PD-1) and cytotoxic T-lymphocyte associated protein-4 (CTLA-4) have been identified as potential markers for enrichment of…

COMPARISON OF SUBCUTANEOUS VERSUS INTRADERMAL ROUTE OF ADMINISTRATION OF MVA VACCINE

Background: Standard subcutaneous (SC) formulation of 3rd-generation modified vaccinia Ankara (MVA-BN) was replaced by the intradermal (ID) administration route (ad.r), owing to shortages in supplies, based on equivalent antibody responses with both (ad.r). Aim was to compare reactogenicity and immunogenicity of the SC vs. ID ad.r. Methods: Self-reports of adverse effects following immunisation (AEFIs) were…

SIALIDASE INHIBITION PREVENTS HIV-MEDIATED INFLAMMATION AND IMMUNE ACTIVATION IN VIVO

Background: Sialylated glycoproteins (proteins containing the glycan sialic acid) are reduced during HIV infection (viremic and antiretroviral-therapy (ART)-suppressed), and levels of sialidase (enzyme cleaving sialic acid) are elevated. Sialylated glycoproteins initiate anti-inflammatory immune responses by engaging the inhibitory sialic-acid binding proteins (Siglecs) expressed on several immune cells. We tested whether inhibiting sialidase, via sialidase inhibitors…

ONE-YEAR TREATMENT WITH PONATINIB INDUCES SUSTAINED CYTOTOXIC ACTIVITY AGAINST HIV

Background: Treatment with tyrosine kinase inhibitors (TKIs) protects CD4 cells from HIV infection, inducing functional cytotoxic populations that eliminate HIV-infected cells. PLWH on ART and dasatinib present reduced reservoir that is resistant to reactivation. We evaluated the persistence of HIV antiviral activity elicited in PBMCs of individuals with chronic myeloid leukemia (CML) after one-year treatment…